VeChain's VeBetter platform logs 48 million sustainable actions across 5.2M wallets. Here's how the B3TR token flywheel actually works. (Read More)VeChain's VeBetter platform logs 48 million sustainable actions across 5.2M wallets. Here's how the B3TR token flywheel actually works. (Read More)

VeChain VeBetter Hits 48M Verified Actions as Token Flywheel Gains Traction

2026/02/24 05:00
3 min read
For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

VeChain VeBetter Hits 48M Verified Actions as Token Flywheel Gains Traction

Rebeca Moen Feb 23, 2026 21:00

VeChain's VeBetter platform logs 48 million sustainable actions across 5.2M wallets. Here's how the B3TR token flywheel actually works.

VeChain VeBetter Hits 48M Verified Actions as Token Flywheel Gains Traction

VeChain's sustainability-focused VeBetter platform has crossed 48 million verified on-chain actions, with participation spanning 5.2 million wallets and more than 50 live applications. The ecosystem's B3TR token, which rewards users for documented eco-friendly behavior, currently sits at a market cap of roughly $4 million.

The numbers behind those actions tell a more tangible story: 412,000 kg of plastic waste reportedly diverted from landfills, 9 MWh of energy saved, and 11 million liters of water conserved. Whether those figures move the needle on climate change is debatable. Whether they're moving tokens into user wallets is not.

How the Two-Token System Works

VeBetter runs on a dual-token model that creates what the project calls a "flywheel" effect—essentially a feedback loop designed to compound engagement over time.

B3TR serves as the reward token. It's capped at 1 billion units and distributed weekly to users who complete verifiable sustainable actions through participating apps. Think logging an EV commute, documenting a recycling drop-off, or tracking a second-hand purchase. Each action gets recorded on VeChain's blockchain, and the verification layer prevents apps from gaming the system—at least in theory. The community can vote out applications that fail to demonstrate genuine impact.

The second token, VOT3, handles governance. Users convert B3TR to VOT3 at a 1:1 ratio, which grants voting rights on how the weekly rewards pool gets allocated across participating apps. Vote participation earns additional B3TR—currently 5% of weekly emissions go to governance rewards.

The Monetization Question

For users wondering if this translates to actual money: B3TR trades on exchanges, so yes, it's liquid. The catch is that value depends entirely on ecosystem growth and sustained demand for the token. Three paths to monetization exist: holding and hoping the ecosystem expands, earning governance rewards through active VOT3 voting, or simply trading accumulated B3TR for other assets.

Unlike airline miles or store loyalty points trapped in corporate databases, B3TR sits in user-controlled wallets. That's a meaningful distinction for anyone who's watched rewards programs devalue or disappear overnight.

What Traders Should Watch

The flywheel model creates an interesting dynamic. More apps mean more users, which drives more VTHO consumption (VeChain's gas token gets burned with each transaction), theoretically creating deflationary pressure on the network level while inflating B3TR supply through weekly distributions.

With 50+ applications already live and some reportedly exceeding one million users, the infrastructure exists. The question is whether sustainable action rewards can maintain user engagement once the novelty fades—a challenge every X-to-Earn model eventually faces. The on-chain verification layer gives VeBetter better odds than most, but the $4 million market cap suggests the market hasn't fully bought in yet.

Image source: Shutterstock
  • vechain
  • b3tr
  • vebetter
  • sustainability
  • web3
Market Opportunity
B3TR Logo
B3TR Price(B3TR)
$0.01013
$0.01013$0.01013
-1.93%
USD
B3TR (B3TR) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09